Sprycel (generic name: dasatinib) is an oral tyrosine kinase inhibitor (TKI) developed to target abnormal proteins that drive uncontrolled cell growth in specific leukemias. It is approved for the treatment of adults and children with Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) in chronic, accelerated, or blast phase, as well as for Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) when other treatments have failed or are not suitable.

Dasatinib works by blocking the activity of the BCR-ABL kinase—the abnormal protein produced by the Philadelphia chromosome—as well as other kinases involved in cancer cell proliferation. By interfering with these signaling pathways, Sprycel helps slow or stop the growth of leukemia cells.

It is taken orally, usually once daily, with or without food. Treatment may continue long term depending on patient response and tolerance.

Common side effects can include low blood cell counts, fluid retention, diarrhea, headache, rash, and fatigue. More serious risks include bleeding, pulmonary arterial hypertension, and heart rhythm problems. Regular monitoring with blood tests and check-ups is required during treatment.

Sprycel offers an important therapeutic option for patients with Ph+ leukemias, particularly when resistance or intolerance to other TKIs (such as imatinib) occurs.